Examiner: YANG, TIAN

Tech Center 1600 • Art Units: 1674

This examiner grants 0% of resolved cases

Performance Statistics

—

Allow Rate

-60.0% vs TC avg

Total Applications

—

Interview Lift

Avg Prosecution Days

Based on 0 resolved cases, 2023–2026

§101 Eligibility

25.0%

§102 Novelty

36.1%

§103 Obviousness

38.9%

§112 Clarity

App #	Title	Status	Assignee
18266717	METHODS OF TREATING DIABETES	Non-Final OA	Eli Lilly and Company
18554236	COMBINATION THERAPY WITH A RAF INHIBITOR AND A PD-1 AXIS INHIBITOR	Non-Final OA	Hanmi Pharm. Co., Ltd.
18028348	THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST ACTING ON ALL OF GLUCAGON, GLP-1 AND GIP RECEPTORS AGAINST MULTIPLE SCLEROSIS	Non-Final OA	HANMI PHARM. CO. ,LTD.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.